Research use only.  Educational reference. Not medical advice. Not for human consumption.
📈 GHRH Analog (Short-Acting)

CJC-1295 without DAC (Mod GRF 1-29) (10 mg Vial) Dosage Protocol

CJC-1295 without DAC (also called Modified GRF 1-29) is a 30-amino-acid synthetic GHRH analog with a half-life of ~30 minutes. It produces a discrete GH pulse rather than sustained elevation.

âš¡ Quickstart Highlights

Vial size
10 mg
Reconstitution
3 mL BAC water → 3.33 mg/mL
1 U-100 unit =
33.3 mcg
Frequency
1–3× daily

Dosing & Reconstitution Guide

Route: Subcutaneous  |  Frequency: 1–3× daily  |  Half-life: ~30 minutes

Standard Approach (3 mL = 3.33 mg/mL)

Reconstituting with 3 mL bacteriostatic water produces a concentration of 3.33 mg/mL. Volume per dose changes with concentration; mg dose itself does not change between vial sizes.

Phase / ProtocolDoseU-100 UnitsVolumeDoses per vial
Weeks 1–2 (titration)100 mcg3 units0.030 mL100 doses
Weeks 3–4150 mcg4.5 units0.045 mL66 doses
Weeks 5–6200 mcg6 units0.060 mL50 doses
Weeks 7–12 (target)250 mcg7.5 units0.075 mL40 doses

Reconstitution Steps

  1. Wipe the vial stopper and BAC water vial with alcohol; let dry.
  2. Draw 3 mL of bacteriostatic water into a sterile syringe.
  3. Inject slowly down the inside glass wall of the peptide vial. Do not aim at the powder.
  4. Gently swirl until fully dissolved. Do not shake.
  5. Label with reconstitution date. Refrigerate at 2–8°C; use within 28 days.

Supplies Needed

Estimates for an 8-week and 12-week cycle at 200 mcg per dose, 1–3× daily (3 doses/week).

Item8-Week Cycle12-Week Cycle
CJC-1295 without DAC (Mod GRF 1-29) (10 mg) vials1 vials1 vials
Insulin syringes (U-100)2436
Bacteriostatic water (10 mL)1 × 10 mL1 × 10 mL
Alcohol swabs1 × 100-pack2 × 100-pack

Protocol Overview

The non-DAC version (Mod GRF 1-29) has a half-life of ~30 minutes — producing a discrete GH pulse rather than sustained elevation. This makes it more physiological than the DAC version but requires more frequent dosing (1–3× daily).

Almost always combined with a GHRP for the synergistic GH-pulse effect — see CJC-1295 + Ipamorelin for the most popular combination.

Dosing Protocol

Daily dosing options:

Cycle structure: 8–12 weeks continuous, then 2–4 week break. Pulsatile pattern preserves natural feedback better than DAC version.

Stacking with GHRP: Almost always combined with ipamorelin or another GHRP — the GHRH+GHRP synergy produces 5–10× larger GH pulses than either alone.

Timing: Avoid eating for 30+ minutes after each dose — meals blunt GH release. Pre-bed dosing aligns with natural overnight pulse during slow-wave sleep.

Storage Instructions

StateTemperatureDuration
Lyophilized−20°C (−4°F)Up to 24 months, dry & dark
Reconstituted2–8°C (35–46°F)Up to 28 days, protect from light

Important Notes

âš  Research Use Only: CJC-1295 without DAC is investigational.

How This Works

CJC-1295 without DAC contains the same four stabilizing amino acid substitutions as the DAC version (D-Ala2, Gln8, Ala15, Leu27) but lacks the albumin-binding linker. The result is a stable, short-acting GHRH analog producing a discrete GH pulse over ~30 minutes.

Common practice combines CJC-1295 with ipamorelin (a GHRP) — the GHRH stimulates GH release while the GHRP synergistically amplifies it, mimicking the body’s natural feedback patterns.

Potential Benefits & Side Effects

Potential Benefits

Side Effect Profile

Lifestyle Factors

Injection Technique

References

1
Sackmann-Sala L et al. 'Short and long-term effects of GHRH agonists' — Endocrinol Metab Clin, 2017